Novo Nordisk has sued about a dozen spas, clinics and pharmacies, over unapproved versions of semaglutide, the active ingredient for its Type 2 diabetes drug Ozempic and weight loss therapy Wegovy.
In late November, the drugmaker filed suit against two Florida compounding pharmacies, Wells Pharmacy and Brooksville Pharmaceuticals, alleging they sell semaglutide therapies containing impurities up to 33% of the product.
The lawsuits are the latest in a series of litigation across the U.S. In June, Novo Nordisk filed lawsuits against six spas and clinics, and the next month saw filed suits against three compounding pharmacies.
The FDA is currently investigating schemes that sell counterfeit versions of Ozempic to unsuspecting pharmacies.